Check out our comprehensive educational activities here

Updates on the SIERRA Trial: An Investigation of Apamistamab-I-131

The SIERRA trial is a randomized phase 3 trial of an investigational radio-immune conjugate. In this activity, Dr. Giralt provides an update on the trial and what he hopes for in the future.

Published on March 9, 2020 in Treatment

Q-TWIST Analysis of Quizartinib vs. Salvage Chemotherapy in Patients with R/R FLT3-ITD AML

There has been much interest in developing new strategies for patients with FLT3-ITD mutated disease. In this activity, Dr. Cortes discusses the role of quizartinib in this setting.

Published on March 6, 2020 in Treatment

Emerging Treatment Options and Maintenance Therapy Following a Stem Cell Transplantation in Patients with AML

In this activity, Dr. Giralt discusses the emerging treatment options and maintenance therapy following a stem cell transplantation in patients with AML.

Published on February 26, 2020 in Treatment

Evolving Treatment Paradigms in AML: New Data and Clinical Trials That Could Change Clinical Practice

The treatment of acute myeloid leukemia (AML) has advanced significantly over the past few years due to an improved understanding of the roles of molecular stratification, clonal heterogeneity, and clonal evolution in therapy and prognostication for patients with the disease. While clinicians have traditionally used factors such as age and performance status (PS) to guide therapy, new and very predictive molecular and chromosomal factors now provide critical information about patient prognosis and can also predict therapy pathways and guide intensity of therapy to improve patient management and overall outcomes.

For more information on developing optimal treatment strategies for your patients with AML, please view the CE Education activity here.

Published on February 17, 2020 in Treatment

Optimizing Outcomes in Relapsed/Refractory AML: Incorporating New Treatments into Practice

The treatment of acute myeloid leukemia (AML) has advanced significantly over the past few years due to an improved understanding of molecular annotation, clonal heterogeneity, and prognostication for patients with leukemia. While clinicians have traditionally used factors such as age and performance status (PS) to guide therapy, newly recognized predictive molecular and chromosomal factors now provide critical information about patient prognosis and can also predict therapy pathways and guide intensity of therapy to improve patient management and overall outcomes.

For more information on developing optimal treatment strategies for your patients with AML, please view the CE Education activity here.

Published on January 27, 2020 in Treatment

Updates on the Most Anticipated Data Presented at ASH 2019

In this clip, Dr. Daver discusses a few exciting studies presented at ASH 2019, including two agents that are especially active.

Published on December 23, 2019 in Treatment

Current and Emerging Therapies in Newly Diagnosed AML: Adapting Treatment to Meet the Needs of the Individual Patient

The treatment of AML has advanced significantly over the past few years, molecular and chromosomal factors now provide critical information which can help guide therapy to improve patient management.

For more information on developing optimal treatment strategies for your patients with AML, please view the CE Education activity here.

Published on November 20, 2019 in Treatment

Development of a Novel NGS-Based Assay for MRD in FLT3-ITD AML

Dr. Levis explains the development of a novel next-generation sequencing assay for MRD in FLT3-ITD mutated AML and its clinical application in patients treated with chemotherapy plus FLT3 inhibitors.

Published on January 4, 2019 in Treatment

Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial

Dr. Stein briefly covers the Beat AML Master Study, including how enasidenib impacts patients with IDH2 mutant AML.

Published on January 4, 2019 in Treatment

An overview of the recently approved combination of venetoclax with azacitidine or decitabine or low-dose cytarabine and where this new option fits in the current treatment paradigm

In this activity, Dr. Harry Erba discusses the combination of venetoclax with azacitidine or decitabine or low-dose cytarabine and where this new option fits in the current treatment paradigm for AML.

Published on December 13, 2018 in Treatment